Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan

Overview of attention for article published in Neuropsychiatric Disease and Treatment, March 2018

Altmetric Badge

Mentioned by

twitter: 1 X user

facebook: 1 Facebook page

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 49 Mendeley

Summary X Facebook Dimensions citations

So far, Dimensions has found 3 publications that cite this research output.

3

The most recent citing publications are shown below. View all 3 publications that cite this research output on Dimensions.

Factors Impeding Switching From Clozapine to Paliperidone Among Patients With Chronic Schizophrenia—A Retrospective Cohort Study

Article in Experimental and Clinical Psychopharmacology (June 2022)

Second-Generation Antipsychotic Drugs for Patients with Schizophrenia: Systematic Literature Review and Meta-analysis of Metabolic and Cardiovascular Side Effects

Article in Clinical Drug Investigation (March 2021)

Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial

Article in Clinical Drug Investigation (December 2018)